Nachrichten zur NeoGenomics Inc. Aktie

Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?

The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after…

NeoGenomics shares jump after revenue forecast tops Street expectations

…

NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript

…

NeoGenomics Q4 2023 Earnings Preview

…

NeoGenomics: Progress, But A New Uncertainty

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors…

Bull of the Day: NeoGenomics (NEO)

Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

NeoGenomics ruling seen having limited impact on estimates, Needham says

…

Natera wins court order barring NeoGenomics from selling RaDaR assay (update)

…

Global Cancer Profiling Market Size To Worth USD 24.36 Billion by 2032 | CAGR of 9.7%

The Global Cancer Profiling Market Size was valued at USD 9.65 Billion in 2022 and the Worldwide Cancer Profiling Market…

NeoGenomics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript

…

Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet

The consensus price target hints at a 35.1% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after…

NeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic Value

…

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.…

Bull of the Day: NeoGenomics (NEO)

Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales…

NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?

NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

Form 10-Q NEOGENOMICS INC For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics, Inc.: NeoGenomics Reports Second Quarter 2023 Results

Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)…

Form 8-K NEOGENOMICS INC For: Aug 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics, Inc.: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced…

NeoGenomics, Inc.: NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics, Inc.: NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics, Inc.: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics, Inc.: NeoGenomics to Showcase the Transformational Impact of RaDaR Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

Form 8-K NEOGENOMICS INC For: May 11

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products

First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products are part of the Zacks Screen of the Week article....…

NeoGenomics cut to market perform at Raymond James on valuation run-up

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics downgraded to market perform from outperform at Raymond James

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the…

NeoGenomics, Inc.: NeoGenomics Reports First Quarter 2023 Results

First Quarter Revenue Increased 17% to $137 MillionFORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)…

NeoGenomics, Inc.: NeoGenomics to Announce First Quarter 2023 Financial Results

FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity

Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article....…

What 9 Analyst Ratings Have To Say About NeoGenomics

Latest Ratings for NEO DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022NeedhamMaintainsBuy Feb 2022Raymond JamesMaintainsOutperform View More…

NeoGenomics, Inc.: NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / April 11, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing…

NeoGenomics, Inc.: NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research Annual Meeting 2023

FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics maintains fiscal 2023 guidance; says improving trends to continue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K NEOGENOMICS INC For: Apr 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics, Inc.: NeoGenomics to Host Investor Day on April 4, 2023

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics launches RaDaR test to detect minimal residual disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics, Inc.: NeoGenomics Announces Commercial Availability of the RaDaR Molecular Residual Disease Test

FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

NeoGenomics stock pops on launch of next-gen sequencing tests

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NeoGenomics, Inc.: NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive - Solid Tumor CGP and Neo Comprehensive - Myeloid Disorders CGP

FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…

dpa-AFX ProFeed